Center to Accelerate Population Research in Alzheimer’s (CAPRA)

加速阿尔茨海默病人群研究中心 (CAPRA)

• 批准号: 10628237
• 负责人: Julie PW Bynum
• 金额: $ 11.81万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628237
• 关键词: Address; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Archives; Area; Behavioral Risk Factor Surveillance System; Caring; Communities; Complex; Consult; Consumption; Country; Data; Data Sources; Dementia; Diffusion; Discipline; Disease; Drug Prescriptions; Economic Policy; Economics; Funding; Future; Goals; Government; Health; Health Policy; Health Services; Health Services Accessibility; Health system; Healthcare; Home; Individual; Infrastructure; Interdisciplinary Study; International; Investigation; Investments; Knowledge; Lead; Leadership; Link; Long-Term Care; Medicare; Methods; Michigan; National Health and Nutrition Examination Survey; Outcome; Personal Satisfaction; Persons; Pilot Projects; Policies; Policy Maker; Population; Population Research; Positioning Attribute; Prevention; Program Development; Public Health; Public Policy; Quality of Care; Ramp; Research; Research Personnel; Research Training; Resource Allocation; Resource Development; Resources; Risk; Science; Societies; Surveys; System; Time; Training; Universities; base; cardiovascular risk factor; cost; design; drug quality; effective therapy; end of life; falls; health care delivery; health care service organization; improved outcome; innovation; multidisciplinary; new technology; novel diagnostics; novel therapeutics; organizational structure; population based; prevent; social; tool

Project Abstract (Overall) The population with Alzheimer’s Disease and related dementias (AD/ADRD) globally is expected to nearly triple by 2050. With few effective treatments either to prevent the disease or slow its progression, we are currently limited to managing established disease and minimizing further negative outcomes, at a cost of $200 billion per year. The National Alzheimer’s Project Act (NAPA) was passed with the goal of reducing the burden of AD/ADRD, not just for persons with dementia but also for the society at large, including the social, economic, and health system effects. There are large gaps in our knowledge about how policy-makers, public health planners and healthcare organizations can best prepare for and respond to the broad population effects of AD/ADRD as we await a cure. The proposed Center to Accelerate Population Research in Alzheimer’s (CAPRA) at the University of Michigan will be focused on science that informs government and healthcare organization actions to address the negative impacts of dementia on the health and financial well-being of individuals and the population. Our focus on public policy and healthcare for persons with dementia falls into four inter-related themes: 1) healthcare delivery and policy impact on outcomes and quality of care, 2) diffusion of new technologies, 3) disparities in quality and access to care, and 4) innovative applications of population data that inform allocation of resources and program development. The CAPRA leadership team is uniquely positioned to leverage its own expertise across these themes and the depth of institutional expertise at the University of Michigan across health services, economic, and population research to accelerate and expand population-based observational AD/ADRD research. The overarching goal for CAPRA is that it will serve as a national resource to enable and expand research by current and future leaders in the study of healthcare delivery, economics, and policies to reduce the burden of AD/ADRD locally, nationally, and internationally. To do so, the Center will act as an “on-ramp” to fast-track junior and established investigators transitioning into AD/ADRD research by funding pilot studies, providing research training and tools, giving access to unique secondary data relevant to AD/ADRD, and developing networks of experts with whom to consult and collaborate. CAPRA seeks to become the leading national resource to promote and accelerate studies that aim to reduce the social, economic, and health burden of AD/ADRD on the population. The research that emanates from this new Center will have real-world implications for health systems, payers, and policymakers as they struggle with designing effective policies to improve outcomes for the growing population with or at risk for AD/ADRD.

项目摘要（总体） 全球患有阿尔茨海默病和相关痴呆症 (AD/ADRD) 的人口预计将接近 到 2050 年，这一数字将增加两倍。几乎没有有效的治疗方法可以预防这种疾病或减缓其进展，我们正在 目前仅限于管理已确定的疾病并最大限度地减少进一步的负面结果，费用为 200 美元 每年十亿。 《国家阿尔茨海默病项目法案》（NAPA）获得通过，目标是减轻负担 AD/ADRD 的影响，不仅针对痴呆症患者，也针对整个社会，包括社会、 经济和卫生系统的影响。对于政策制定者、公众如何 健康规划者和医疗保健组织可以最好地准备和应对广泛的人口影响 当我们等待治愈方法时，我们会发现 AD/ADRD 的症状。拟议的加速阿尔茨海默病人口研究中心 密歇根大学 (CAPRA) 将专注于为政府和医疗保健提供信息的科学 组织采取行动解决痴呆症对健康和财务福祉的负面影响 个人和人口。我们对痴呆症患者的公共政策和医疗保健的关注点包括 四个相互关联的主题：1) 医疗保健提供和政策对结果和护理质量的影响，2) 扩散 新技术的应用，3) 质量和获得护理的机会的差异，以及 4) 人口的创新应用 为资源分配和计划开发提供信息的数据。 CAPRA 领导团队是独一无二的 定位于利用自己在这些主题上的专业知识以及机构专业知识的深度 密歇根大学在医疗服务、经济和人口领域的研究加速和扩展 基于人群的观察性 AD/ADRD 研究。 CAPRA 的总体目标是，它将作为一个 国家资源，以支持和扩大当前和未来医疗保健研究领导者的研究 减轻当地、国家和国际 AD/ADRD 负担的交付、经济和政策。到 为此，该中心将充当快速通道，帮助初级和成熟的研究人员过渡到 AD/ADRD 研究通过资助试点研究、提供研究培训和工具、提供独特的 与 AD/ADRD 相关的二手数据，以及建立可咨询和咨询的专家网络 合作。 CAPRA 致力于成为领先的国家资源，以促进和加速旨在 减少AD/ADRD给人们带来的社会、经济和健康负担。所产生的研究 这个新中心的成果将对卫生系统、支付者和政策制定者产生现实世界的影响，因为他们 努力设计有效的政策来改善不断增长的患有或面临风险的人口的结果 AD/ADRD。